Search results for "INCIDENCE"

showing 10 items of 2270 documents

Long-term residential road traffic noise and mortality in a Danish cohort.

2020

Transportation noise is a growing public health concern worldwide and epidemiological evidence has linked road traffic noise with mortality. However, incongruent effect estimates have been reported between incidence and mortality studies. Therefore, the present study aimed to investigate whether long-term exposure to residential road traffic noise at the most and least exposed façades was associated with all-cause, cardiovascular disease (CVD), ischemic heart disease (IHD), stroke, respiratory, or cancer mortality in a Danish cohort study. In a cohort of 52,758 individuals from Copenhagen and Aarhus, we estimated road traffic noise at the most and least exposed façades, as well as ambient a…

medicine.medical_specialtyDenmark010501 environmental sciences01 natural sciencesBiochemistryCohort Studies03 medical and health sciences0302 clinical medicineInterquartile rangeEnvironmental healthAir PollutionEpidemiologyRisk of mortalityMedicineHumans030212 general & internal medicine0105 earth and related environmental sciencesGeneral Environmental ScienceCause of deathbusiness.industryProportional hazards modelIncidence (epidemiology)Environmental ExposureNoise TransportationCohortbusinessCohort studyEnvironmental research
researchProduct

The genetic epidemiology of unipolar depression and panic disorder.

1993

medicine.medical_specialtyDepressive DisorderBipolar DisorderPanic disorderIncidenceComorbiditymedicine.diseasePsychiatry and Mental healthCross-Sectional StudiesGenetic epidemiologyGermanyAdoptionmedicineDiseases in TwinsHumansPanic DisorderPharmacology (medical)PsychiatryPsychologyDepression (differential diagnoses)International clinical psychopharmacology
researchProduct

SGLT2 inhibitors in T2D and associated comorbidities - differentiating within the class

2019

Abstract Background For patients with type 2 diabetes (T2D), cardiovascular disease (CVD) is the single most common cause of mortality. In 2008 and 2012, the Federal Drug Administration (FDA) and the European Medicines Agency (EMA) respectively mandated cardiovascular outcomes trials (CVOTs) on all new anti-diabetic agents, as prospective trials statistically powered to rule out excess cardiovascular risk in patients with T2D. Unexpectedly, some of these CVOTs have demonstrated not only cardiovascular safety, but also cardioprotective effects, as was first shown for the SGLT2 inhibitor empagliflozin in EMPA-REG OUTCOME. Expert opinion To debate newly available CVOT data and to put them into…

medicine.medical_specialtyDiabetes mellitus type 2 ; drug therapy ; Cardiovascular diseases ; drug therapy ; Canagliflozin ; therapeutic use ; Benzhydryl compounds ; therapeutic use ; Glucosides ; therapeutic use ; Sodium-Glucose Transporter 2 Inhibitors ; therapeutic useEndocrinology Diabetes and MetabolismEmpagliflozin610 Medicine & health030209 endocrinology & metabolismContext (language use)ComorbidityType 2 diabetesDiseaseCanagliflozin ; Cardiovascular disease ; Dapagliflozin ; Empagliflozin ; SGLT2 inhibitor ; Type 2 diabetes.lcsh:Diseases of the endocrine glands. Clinical endocrinology03 medical and health scienceschemistry.chemical_compound0302 clinical medicineDiabetes mellitusCorrespondenceEmpagliflozinHumansMedicine030212 general & internal medicineCanagliflozinDapagliflozinIntensive care medicineSodium-Glucose Transporter 2 InhibitorsCanagliflozinlcsh:RC648-665business.industryIncidence616.379-008.64 [udc]Type 2 diabetesSGLT2 inhibitorGeneral MedicineDapagliflozinCardiovascular diseasePrognosismedicine.disease3. Good healthEastern europeanDiabetes Mellitus Type 2chemistryCardiovascular Diseasesbusinessmedicine.drug
researchProduct

Chronic kidney disease and dialysis therapy: incidence and prevalence in the world

2021

Сhronic kidney disease (CKD) is the important public and medical problem in the world because of a large burden on health care systems. The prevalence of CKD and number of dialysis patients are increasing in the world. The prevalence and incidence of CKD depends on age, race, and gender of patients, region, and the presence of the CKD registry in a country. Diabetes mellitus (DM) and arterial hypertension (AH) are the most common causes of end stage renal disease (ESRD). It is projected that the number of dialysis patients will reach 5.5 million in 2030. Specific strategies and interventions should be urgently aimed at reducing in the burden of CKD by means of the prevention, detection and …

medicine.medical_specialtyDialysis Therapyhemodialysisbusiness.industryIncidence (epidemiology)030232 urology & nephrologyPharmaceutical SciencePharmacymedicine.diseaseurologic and male genital diseasesfemale genital diseases and pregnancy complicationsRS1-44103 medical and health sciences0302 clinical medicinePharmacy and materia medicaperitoneal dialysisInternal medicinemedicinePharmacology (medical)030212 general & internal medicinebusinesschronic kidney diseaseKidney diseaseFarmatsija
researchProduct

AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION (AUTOHSCT) IN CLL: FIRST RESULTS OF AN EBMT RANDOMIZED TRIAL COMPARING AUTOTRANSPLANT VERSUS WAIT …

2010

Abstract Abstract 877 This phase-III randomized EBMT-intergroup trial studied the impact of a consolidating autoHSCT vs no consolidation for patients with CLL in Binet stage A progressive, B or C , in CR, nodular PR or VGPR after first or second line therapy. The primary objective was to show that autoHSCT increased the 5-year progression-free survival (PFS) by 30%. Although it had been calculated that 270 patients were to be randomized, the study was terminated by the steering committee in July 2007 due to poor accrual. Here we present a first analysis based on 69% of expected follow-up forms. Results: Between November 2001 and July 2007, 223 patients were enrolled (SFGM-TC/FCLLG n=98, MRC…

medicine.medical_specialtyDisease statusRandomizationbusiness.industrymedicine.medical_treatmentIncidence (epidemiology)ImmunologyCell BiologyHematologyHematopoietic stem cell transplantationBiochemistrySurgerylaw.inventionRandomized controlled triallawInternal medicinemedicineIn patientProgression-free survivalStage (cooking)business
researchProduct

Colesterol-no HDL como objetivo terapéutico

2019

Although cholesterol linked to low-density lipoproteins (c-LDL) is well established as a risk factor for cardiovascular disease, there is often a more complex dyslipidaemia pattern that contributes to the formation of atherosclerotic plaque. Non-HDL cholesterol (c-NO-HDL) is used to estimate the total amount of atherogenic lipoproteins in plasma, some of which are not usually determined in daily clinical practice. c-NO-HDL is easily calculated from the subtraction of total plasma cholesterol from the cholesterol content carried by high density lipoproteins. The c-NO-HDL has a predictive value superior to that of C-LDL to estimate the risk of major cardiovascular events in epidemiological st…

medicine.medical_specialtyDisease030204 cardiovascular system & hematologyArteriosclerotic heart diseaselaw.invention03 medical and health scienceschemistry.chemical_compound0302 clinical medicineRandomized controlled triallawInternal medicineEpidemiologyMedicinePharmacology (medical)030212 general & internal medicineRisk factorbusiness.industryCholesterolIncidence (epidemiology)medicine.diseaseClinical trialchemistryCardiologylipids (amino acids peptides and proteins)Cardiology and Cardiovascular MedicinebusinessClínica e Investigación en Arteriosclerosis
researchProduct

Subclinical atrial fibrillation: how hard should we look?

2012

More than three decades ago, an analysis from the Framingham Heart Study revealed that atrial fibrillation (AF) increases the risk of stroke by a factor of five in non-rheumatic AF and by a factor of 17 in rheumatic AF.1 Since then, it has convincingly been shown that anticoagulation is one of the most effective secondary stroke prophylactic treatment options, which reduces the risk of stroke by 2/3,2 even in an older population.3 AF may occur in different types and in an individual patient often starts with paroxysmal AF, but later becomes persistent or permanent AF.4 Interestingly, the risk of stroke or systemic embolism is influenced by cardiovascular risk factors such as hypertension, d…

medicine.medical_specialtyDisease030204 cardiovascular system & hematologyGlobal HealthAsymptomatic03 medical and health sciences0302 clinical medicineFramingham Heart StudyRisk FactorsInternal medicineAtrial FibrillationmedicineHumansClinical significancecardiovascular diseasesStrokeSubclinical infectionAgedbusiness.industryIncidenceCardiac Pacing ArtificialAnticoagulantsAtrial fibrillationmedicine.diseasePrognosis3. Good healthStrokeCardiologymedicine.symptomCardiology and Cardiovascular Medicinebusiness030217 neurology & neurosurgeryAtrial flutterHeart (British Cardiac Society)
researchProduct

Pharmacokinetic evaluation of esomeprazole for the treatment of gastroesophageal reflux disease

2014

Proton pump inhibitors (PPIs) are widely used for the treatment of acid-related diseases such as gastroesophageal reflux disease (GERD). They are recommended by the American College of Gastroenterology for healing erosive esophagitis (EO) and as long-term treatment in patients with healed EO. The available PPIs differ somewhat in their pharmacokinetics and clinical properties, but whether these differences are of clinical relevance is a matter of debate. Some safety concerns have been raised with the use of PPIs, mostly an increased incidence of infectious diseases such as community-acquired pneumonia or Clostridium difficile diarrhea.This article explores the results of clinical studies on…

medicine.medical_specialtyDiseaseToxicologyGastroenterologyEsomeprazolePharmacokineticsInternal medicinemedicineEsophagitisHumansClinical significanceIntensive care medicinePharmacologybusiness.industryIncidenceIncidence (epidemiology)Public healthEsomeprazoleProton Pump InhibitorsStereoisomerismGeneral Medicinemedicine.diseasePneumoniaGastroesophageal RefluxGERDbusinessmedicine.drugExpert Opinion on Drug Metabolism & Toxicology
researchProduct

The incidence of psychotic disorders among migrants and minority ethnic groups in Europe: findings from the multinational EU-GEI study

2022

AbstractBackgroundIn Europe, the incidence of psychotic disorder is high in certain migrant and minority ethnic groups (hence: ‘minorities’). However, it is unknown how the incidence pattern for these groups varies within this continent. Our objective was to compare, across sites in France, Italy, Spain, the UK and the Netherlands, the incidence rates for minorities and the incidence rate ratios (IRRs, minorities v. the local reference population).MethodsThe European Network of National Schizophrenia Networks Studying Gene–Environment Interactions (EU-GEI) study was conducted between 2010 and 2015. We analyzed data on incident cases of non-organic psychosis (International Classification of …

medicine.medical_specialtyDopamineRegion of originEthnic groupmigrationpsychosistress03 medical and health sciencesRace (biology)0302 clinical medicineEpidemiologymedicineHumanspsychosis10. No inequalityraceMinority GroupsApplied PsychologyTransients and MigrantsHigh rateIncidenceIncidence (epidemiology)Social environmentPREVALENCE030227 psychiatry3. Good healthEuropeschizophreniaPsychiatry and Mental healthGeographyPsychotic DisordersMultinational corporation1ST-CONTACT INCIDENCEethnicityepidemiology030217 neurology & neurosurgerySOCIAL DEFEAT HYPOTHESISDemographyPsychological Medicine
researchProduct

A 15-Year Perspective of the Fabry Outcome Survey

2016

Abstract The Fabry Outcome Survey (FOS) is an international long-term observational registry sponsored by Shire for patients diagnosed with Fabry disease who are receiving or are candidates for therapy with agalsidase alfa (agalα). Established in 2001, FOS provides long-term data on agalα safety/efficacy and collects data on the natural history of Fabry disease, with the aim of improving clinical management. The FOS publications have helped establish prognostic and severity scores, defined the incidence of specific disease variants and implications for clinical management, described clinical manifestations in special populations, confirmed the high prevalence of cardiac morbidity, and demon…

medicine.medical_specialtyEndocrinology Diabetes and MetabolismDisease030204 cardiovascular system & hematologyoutcomesFabry Outcome Survey03 medical and health sciences0302 clinical medicineInternal medicinemedicineGenetics (clinical)lcsh:R5-920agalsidase alfaFabry diseasebusiness.industryIncidence (epidemiology)Therapeutic effectEnzyme replacement therapymedicine.diseaseFabry diseaseNatural historyPediatrics Perinatology and Child HealthPhysical therapyObservational studybusinesslcsh:Medicine (General)Agalsidase alfa030217 neurology & neurosurgeryenzyme replacement therapy
researchProduct